+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07237516

Observational Study of Zymfentra Infliximab-dyyb for Adults with Crohns Disease, Ulcerative Colitis, or Indeterminate Colitis Over One Year

Led by University of North Carolina, Chapel Hill · Updated on 2026-08-05

200

Participants Needed

11

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying how effective Zymfentra infliximab-dyyb is in treating adults with Crohns disease, ulcerative colitis, or inflammatory bowel disease unclassified. This observational study focuses on patients prescribed Zymfentra as part of their regular care to see if it reduces symptoms over one year. The study is sponsored by the University of North Carolina, Chapel Hill. Participants receive Zymfentra treatment through their standard medical care. They will be followed for one year while answering online surveys about their bowel habits and other health outcomes at specific weeks throughout the study period. The study collects patient-reported outcomes and clinical remission data at multiple time points including weeks 0, 1, 2, 4, 6, 10, 14, 18, 24, 36, and 52. During participation, patients complete questionnaires that assess symptoms, depression, anxiety, social satisfaction, fatigue, and work productivity. Clinical remission is evaluated using established disease activity indices. Researchers also monitor mucosal healing through standard tests and endoscopic scores when available. The total study duration for each participant is one year, with ongoing monitoring of responses and disease activity.

CONDITIONS

Brief Title

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Research Team

S

Susan Jackson

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here